CA2830731A1 - Traitement de cancers avec des inhibiteurs de micro-arn - Google Patents

Info

Publication number

CA2830731A1

CA2830731A1 CA 2830731 CA2830731A CA2830731A1 CA 2830731 A1 CA2830731 A1 CA 2830731A1 CA 2830731 CA2830731 CA 2830731 CA 2830731 A CA2830731 A CA 2830731A CA 2830731 A1 CA2830731 A1 CA 2830731A1

Authority

CA

Canada

Prior art keywords

mir

cells

cancer

inhibitor

tet2

Prior art date

2013-10-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 136
• 238000011282 treatment Methods 0.000 title abstract description 36
• 229940122938 MicroRNA inhibitor Drugs 0.000 title description 2
• 108091062170 Mir-22 Proteins 0.000 claims abstract description 352
• 206010006187 Breast cancer Diseases 0.000 claims abstract description 78
• 239000003112 inhibitor Substances 0.000 claims abstract description 77
• 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 72
• 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 50
• 230000000295 complement effect Effects 0.000 claims abstract description 33
• 230000000694 effects Effects 0.000 claims abstract description 31
• 210000004369 blood Anatomy 0.000 claims abstract description 28
• 239000008280 blood Substances 0.000 claims abstract description 28
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 23
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 23
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 21
• 230000014509 gene expression Effects 0.000 claims description 100
• 201000011510 cancer Diseases 0.000 claims description 72
• 239000000074 antisense oligonucleotide Substances 0.000 claims description 66
• 238000012230 antisense oligonucleotides Methods 0.000 claims description 66
• 238000000034 method Methods 0.000 claims description 56
• 108090000623 proteins and genes Proteins 0.000 claims description 50
• 206010027476 Metastases Diseases 0.000 claims description 37
• 125000003729 nucleotide group Chemical group 0.000 claims description 34
• 239000002773 nucleotide Substances 0.000 claims description 33
• 230000009401 metastasis Effects 0.000 claims description 28
• 208000032839 leukemia Diseases 0.000 claims description 27
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 21
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 21
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 13
• 230000002829 reductive effect Effects 0.000 claims description 12
• 230000007423 decrease Effects 0.000 claims description 11
• -1 hexitol nucleic acids Chemical class 0.000 claims description 11
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 11
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 9
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 9
• 238000007385 chemical modification Methods 0.000 claims description 9
• 206010025323 Lymphomas Diseases 0.000 claims description 8
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
• 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 claims description 8
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 8
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
• 208000017604 Hodgkin disease Diseases 0.000 claims description 6
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 6
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
• 241000124008 Mammalia Species 0.000 claims description 6
• 108091093037 Peptide nucleic acid Proteins 0.000 claims description 6
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
• 230000003831 deregulation Effects 0.000 claims description 2
• 101150015730 Prlr gene Proteins 0.000 claims 1
• 239000002679 microRNA Substances 0.000 abstract description 101
• 108091070501 miRNA Proteins 0.000 abstract description 98
• 239000003795 chemical substances by application Substances 0.000 abstract description 21
• 230000002265 prevention Effects 0.000 abstract description 18
• 108700011259 MicroRNAs Proteins 0.000 abstract description 11
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 3
• 210000004027 cell Anatomy 0.000 description 171
• 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 111
• 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 111
• 241000699670 Mus sp. Species 0.000 description 99
• 210000002754 ksl cell Anatomy 0.000 description 51
• 239000013598 vector Substances 0.000 description 33
• 108091027977 Mir-200 Proteins 0.000 description 32
• 238000011830 transgenic mouse model Methods 0.000 description 32
• 238000004458 analytical method Methods 0.000 description 30
• 230000007705 epithelial mesenchymal transition Effects 0.000 description 30
• 238000001727 in vivo Methods 0.000 description 30
• 241000699660 Mus musculus Species 0.000 description 29
• 102000043123 TET family Human genes 0.000 description 29
• 108091084976 TET family Proteins 0.000 description 29
• 230000002246 oncogenic effect Effects 0.000 description 26
• 230000004083 survival effect Effects 0.000 description 26
• 210000001185 bone marrow Anatomy 0.000 description 25
• 231100000590 oncogenic Toxicity 0.000 description 25
• 239000005090 green fluorescent protein Substances 0.000 description 23
• 230000002018 overexpression Effects 0.000 description 22
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 21
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 21
• 101000653369 Homo sapiens Methylcytosine dioxygenase TET3 Proteins 0.000 description 21
• 102100030812 Methylcytosine dioxygenase TET3 Human genes 0.000 description 21
• 238000011529 RT qPCR Methods 0.000 description 21
• 239000000203 mixture Substances 0.000 description 21
• 230000009467 reduction Effects 0.000 description 21
• 238000002054 transplantation Methods 0.000 description 21
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
• 210000001519 tissue Anatomy 0.000 description 20
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 19
• 201000010099 disease Diseases 0.000 description 19
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
• 238000011536 re-plating Methods 0.000 description 18
• 230000000670 limiting effect Effects 0.000 description 17
• 210000004072 lung Anatomy 0.000 description 17
• 238000003556 assay Methods 0.000 description 16
• 102100038595 Estrogen receptor Human genes 0.000 description 15
• 239000003814 drug Substances 0.000 description 15
• 230000005014 ectopic expression Effects 0.000 description 15
• 102000004169 proteins and genes Human genes 0.000 description 15
• 230000008685 targeting Effects 0.000 description 15
• 230000006870 function Effects 0.000 description 14
• 230000005764 inhibitory process Effects 0.000 description 14
• 108020004999 messenger RNA Proteins 0.000 description 14
• 102000040430 polynucleotide Human genes 0.000 description 14
• 108091033319 polynucleotide Proteins 0.000 description 14
• 239000002157 polynucleotide Substances 0.000 description 14
• 108020004414 DNA Proteins 0.000 description 13
• 210000005087 mononuclear cell Anatomy 0.000 description 13
• 230000001973 epigenetic effect Effects 0.000 description 12
• 108010038795 estrogen receptors Proteins 0.000 description 12
• 238000000338 in vitro Methods 0.000 description 12
• 210000005075 mammary gland Anatomy 0.000 description 12
• 210000004216 mammary stem cell Anatomy 0.000 description 12
• 108091074450 miR-200c stem-loop Proteins 0.000 description 12
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 11
• 108020005345 3' Untranslated Regions Proteins 0.000 description 11
• 230000030279 gene silencing Effects 0.000 description 11
• 230000004048 modification Effects 0.000 description 11
• 238000012986 modification Methods 0.000 description 11
• 238000001262 western blot Methods 0.000 description 11
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 10
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 10
• 238000011161 development Methods 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 230000003394 haemopoietic effect Effects 0.000 description 10
• 230000001394 metastastic effect Effects 0.000 description 10
• 206010061289 metastatic neoplasm Diseases 0.000 description 10
• 210000005259 peripheral blood Anatomy 0.000 description 10
• 239000011886 peripheral blood Substances 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 9
• 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 9
• 210000000481 breast Anatomy 0.000 description 9
• 230000011132 hemopoiesis Effects 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 239000013610 patient sample Substances 0.000 description 9
• 102000003998 progesterone receptors Human genes 0.000 description 9
• 108090000468 progesterone receptors Proteins 0.000 description 9
• 230000001177 retroviral effect Effects 0.000 description 9
• 210000000130 stem cell Anatomy 0.000 description 9
• RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 208000009527 Refractory anemia Diseases 0.000 description 8
• 230000001332 colony forming effect Effects 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 238000000684 flow cytometry Methods 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 210000000265 leukocyte Anatomy 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 208000025113 myeloid leukemia Diseases 0.000 description 8
• 239000008194 pharmaceutical composition Substances 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 7
• 206010027458 Metastases to lung Diseases 0.000 description 7
• 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 210000001772 blood platelet Anatomy 0.000 description 7
• 230000003828 downregulation Effects 0.000 description 7
• 230000002489 hematologic effect Effects 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 6
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 6
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 6
• 230000002159 abnormal effect Effects 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 210000000981 epithelium Anatomy 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 238000007901 in situ hybridization Methods 0.000 description 6
• 108091059199 miR-200a stem-loop Proteins 0.000 description 6
• 239000002243 precursor Substances 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 210000000952 spleen Anatomy 0.000 description 6
• 210000002536 stromal cell Anatomy 0.000 description 6
• 235000000346 sugar Nutrition 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 208000022679 triple-negative breast carcinoma Diseases 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• 102100032187 Androgen receptor Human genes 0.000 description 5
• 208000005623 Carcinogenesis Diseases 0.000 description 5
• 108091029523 CpG island Proteins 0.000 description 5
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 5
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 5
• 108091027967 Small hairpin RNA Proteins 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• 108010080146 androgen receptors Proteins 0.000 description 5
• 230000002001 anti-metastasis Effects 0.000 description 5
• 210000000601 blood cell Anatomy 0.000 description 5
• 230000036952 cancer formation Effects 0.000 description 5
• 231100000504 carcinogenesis Toxicity 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 230000012292 cell migration Effects 0.000 description 5
• 238000000546 chi-square test Methods 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• 239000006185 dispersion Substances 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 230000000925 erythroid effect Effects 0.000 description 5
• 238000002991 immunohistochemical analysis Methods 0.000 description 5
• 238000001325 log-rank test Methods 0.000 description 5
• 208000003747 lymphoid leukemia Diseases 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 210000000066 myeloid cell Anatomy 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• 238000004393 prognosis Methods 0.000 description 5
• 206010067959 refractory cytopenia with multilineage dysplasia Diseases 0.000 description 5
• 239000004055 small Interfering RNA Substances 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 206010000830 Acute leukaemia Diseases 0.000 description 4
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101000836112 Homo sapiens Nuclear body protein SP140 Proteins 0.000 description 4
• 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 4
• 108010070511 Keratin-8 Proteins 0.000 description 4
• 102100025638 Nuclear body protein SP140 Human genes 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 4
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 4
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
• 206010038272 Refractory anaemia with ringed sideroblasts Diseases 0.000 description 4
• 206010041660 Splenomegaly Diseases 0.000 description 4
• 230000001594 aberrant effect Effects 0.000 description 4
• 208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 208000007502 anemia Diseases 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 210000003995 blood forming stem cell Anatomy 0.000 description 4
• 239000013592 cell lysate Substances 0.000 description 4
• 230000000973 chemotherapeutic effect Effects 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 238000010195 expression analysis Methods 0.000 description 4
• 239000013604 expression vector Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 230000009368 gene silencing by RNA Effects 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 208000014951 hematologic disease Diseases 0.000 description 4
• 230000002779 inactivation Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 230000009545 invasion Effects 0.000 description 4
• 230000007774 longterm Effects 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 238000009099 neoadjuvant therapy Methods 0.000 description 4
• 238000007747 plating Methods 0.000 description 4
• 238000007634 remodeling Methods 0.000 description 4
• 125000002652 ribonucleotide group Chemical group 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 238000013456 study Methods 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 230000002103 transcriptional effect Effects 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 230000003827 upregulation Effects 0.000 description 4
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 4
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 102000000905 Cadherin Human genes 0.000 description 3
• 108050007957 Cadherin Proteins 0.000 description 3
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
• 206010068051 Chimerism Diseases 0.000 description 3
• 108010051219 Cre recombinase Proteins 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• 208000006402 Ductal Carcinoma Diseases 0.000 description 3
• 206010058314 Dysplasia Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
• 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 description 3
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
• 108030004080 Methylcytosine dioxygenases Proteins 0.000 description 3
• 108091030146 MiRBase Proteins 0.000 description 3
• 108010002519 Prolactin Receptors Proteins 0.000 description 3
• 102100029000 Prolactin receptor Human genes 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 108091036066 Three prime untranslated region Proteins 0.000 description 3
• 238000009098 adjuvant therapy Methods 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 230000032823 cell division Effects 0.000 description 3
• 230000003915 cell function Effects 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 210000000805 cytoplasm Anatomy 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 230000017858 demethylation Effects 0.000 description 3
• 238000010520 demethylation reaction Methods 0.000 description 3
• 239000005547 deoxyribonucleotide Substances 0.000 description 3
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 230000010393 epithelial cell migration Effects 0.000 description 3
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 239000011737 fluorine Substances 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 208000035474 group of disease Diseases 0.000 description 3
• 201000009277 hairy cell leukemia Diseases 0.000 description 3
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
• 206010020718 hyperplasia Diseases 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 230000008595 infiltration Effects 0.000 description 3
• 238000001764 infiltration Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 230000001926 lymphatic effect Effects 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
• 230000011987 methylation Effects 0.000 description 3
• 238000007069 methylation reaction Methods 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 229960004857 mitomycin Drugs 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 239000002777 nucleoside Substances 0.000 description 3
• 210000004940 nucleus Anatomy 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 230000001629 suppression Effects 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
• FICVQGAXQTVNNK-JHYUDYDFSA-N 4-amino-1-[(2r,4s,5s)-4-hydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](NO)[C@@H](O)C1 FICVQGAXQTVNNK-JHYUDYDFSA-N 0.000 description 2
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
• FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 2
• 241000272517 Anseriformes Species 0.000 description 2
• 241000586555 Aulacaspis rosae Species 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 206010055113 Breast cancer metastatic Diseases 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 208000009458 Carcinoma in Situ Diseases 0.000 description 2
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
• 208000006029 Cardiomegaly Diseases 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
• 239000012650 DNA demethylating agent Substances 0.000 description 2
• 229940045805 DNA demethylating agent Drugs 0.000 description 2
• 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
• 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 102100037362 Fibronectin Human genes 0.000 description 2
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
• 102100021454 Histone deacetylase 4 Human genes 0.000 description 2
• 101710177324 Histone deacetylase 4 Proteins 0.000 description 2
• 101000632178 Homo sapiens Homeobox protein Nkx-2.1 Proteins 0.000 description 2
• 101000845269 Homo sapiens Transcription termination factor 1 Proteins 0.000 description 2
• 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 2
• 108091092195 Intron Proteins 0.000 description 2
• 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 2
• 108010066321 Keratin-14 Proteins 0.000 description 2
• 102000011782 Keratins Human genes 0.000 description 2
• 108010076876 Keratins Proteins 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
• 208000000265 Lobular Carcinoma Diseases 0.000 description 2
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
• 241000713333 Mouse mammary tumor virus Species 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
• 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 2
• 238000000636 Northern blotting Methods 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 description 2
• 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• 108091028664 Ribonucleotide Proteins 0.000 description 2
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 108010041191 Sirtuin 1 Proteins 0.000 description 2
• 238000002105 Southern blotting Methods 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• 206010042971 T-cell lymphoma Diseases 0.000 description 2
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 2
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
• 102100034549 Transcriptional activator protein Pur-beta Human genes 0.000 description 2
• 101710118350 Transcriptional activator protein Pur-beta Proteins 0.000 description 2
• 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
• 206010064390 Tumour invasion Diseases 0.000 description 2
• 108010065472 Vimentin Proteins 0.000 description 2
• 102000013127 Vimentin Human genes 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 108010012198 Zinc Finger E-box Binding Homeobox 2 Proteins 0.000 description 2
• 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 description 2
• GELQGNSEMRPIQJ-UHFFFAOYSA-N [[4,6-bis(dimethylamino)-1,3,5-triazin-2-yl]-methylamino]methanol Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)CO)=N1 GELQGNSEMRPIQJ-UHFFFAOYSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 210000000577 adipose tissue Anatomy 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 238000011256 aggressive treatment Methods 0.000 description 2
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 229960000074 biopharmaceutical Drugs 0.000 description 2
• 238000010322 bone marrow transplantation Methods 0.000 description 2
• 210000000069 breast epithelial cell Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 230000009400 cancer invasion Effects 0.000 description 2
• 230000004709 cell invasion Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 208000024207 chronic leukemia Diseases 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 230000002559 cytogenic effect Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 229960001433 erlotinib Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 238000013401 experimental design Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
• 206010017758 gastric cancer Diseases 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 230000009033 hematopoietic malignancy Effects 0.000 description 2
• 208000018706 hematopoietic system disease Diseases 0.000 description 2
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
• 230000006607 hypermethylation Effects 0.000 description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
• 238000010166 immunofluorescence Methods 0.000 description 2
• 238000010185 immunofluorescence analysis Methods 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 229960001691 leucovorin Drugs 0.000 description 2
• 238000003468 luciferase reporter gene assay Methods 0.000 description 2
• 201000005249 lung adenocarcinoma Diseases 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 230000004563 mammosphere formation Effects 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 208000037819 metastatic cancer Diseases 0.000 description 2
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
• 239000000693 micelle Substances 0.000 description 2
• 238000010232 migration assay Methods 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 239000003607 modifier Substances 0.000 description 2
• 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 2
• 230000000683 nonmetastatic effect Effects 0.000 description 2
• 150000003833 nucleoside derivatives Chemical class 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
• 108091007428 primary miRNA Proteins 0.000 description 2
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 239000002510 pyrogen Substances 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 206010038038 rectal cancer Diseases 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 239000002336 ribonucleotide Substances 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000017105 transposition Effects 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 210000005048 vimentin Anatomy 0.000 description 2
• KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• WVKOPZMDOFGFAK-UHFFFAOYSA-N 4-hydroperoxycyclophosphamide Chemical compound OOC1=NP(O)(N(CCCl)CCCl)OCC1 WVKOPZMDOFGFAK-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 230000007730 Akt signaling Effects 0.000 description 1
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
• 208000000058 Anaplasia Diseases 0.000 description 1
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
• 102100036008 CD48 antigen Human genes 0.000 description 1
• 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
• 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 102000004225 Cathepsin B Human genes 0.000 description 1
• 108090000712 Cathepsin B Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 238000007808 Cell invasion assay Methods 0.000 description 1
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
• 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
• 102100021906 Cyclin-O Human genes 0.000 description 1
• 230000007067 DNA methylation Effects 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
• 108091035710 E-box Proteins 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241000272496 Galliformes Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
• 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
• 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 description 1
• 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
• 101001053339 Homo sapiens Inositol polyphosphate 4-phosphatase type II Proteins 0.000 description 1
• 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
• 101000653360 Homo sapiens Methylcytosine dioxygenase TET1 Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 108700002232 Immediate-Early Genes Proteins 0.000 description 1
• 102100024366 Inositol polyphosphate 4-phosphatase type II Human genes 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 101710203526 Integrase Proteins 0.000 description 1
• 102100032816 Integrin alpha-6 Human genes 0.000 description 1
• 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
• 201000003791 MALT lymphoma Diseases 0.000 description 1
• 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• 208000006395 Meigs Syndrome Diseases 0.000 description 1
• 206010027139 Meigs' syndrome Diseases 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 102100030819 Methylcytosine dioxygenase TET1 Human genes 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 101100182714 Mus musculus Ly6c1 gene Proteins 0.000 description 1
• 108050000637 N-cadherin Proteins 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
• 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 208000031816 Pathologic Dilatation Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 201000008691 Pelger-Huet Anomaly Diseases 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• 206010048734 Phakomatosis Diseases 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• 206010035774 Poikilocytosis Diseases 0.000 description 1
• 206010036040 Polychromasia Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
• 102000009572 RNA Polymerase II Human genes 0.000 description 1
• 108010009460 RNA Polymerase II Proteins 0.000 description 1
• 102000014450 RNA Polymerase III Human genes 0.000 description 1
• 108010078067 RNA Polymerase III Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 108010052090 Renilla Luciferases Proteins 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 108091006629 SLC13A2 Proteins 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 102100038081 Signal transducer CD24 Human genes 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 101150012475 TET2 gene Proteins 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 102000011410 Zinc Finger E-box-Binding Homeobox 1 Human genes 0.000 description 1
• 108010023606 Zinc Finger E-box-Binding Homeobox 1 Proteins 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 150000003838 adenosines Chemical class 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 229940098174 alkeran Drugs 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000000063 antileukemic agent Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000000823 artificial membrane Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 210000002960 bfu-e Anatomy 0.000 description 1
• 229940108502 bicnu Drugs 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 201000009036 biliary tract cancer Diseases 0.000 description 1
• 208000020790 biliary tract neoplasm Diseases 0.000 description 1
• 238000007622 bioinformatic analysis Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 238000007469 bone scintigraphy Methods 0.000 description 1
• 201000000220 brain stem cancer Diseases 0.000 description 1
• 201000003714 breast lobular carcinoma Diseases 0.000 description 1
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 229940088954 camptosar Drugs 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 230000010343 cardiac dilation Effects 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000009956 central mechanism Effects 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 210000002791 cfu-m Anatomy 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 238000011976 chest X-ray Methods 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 239000012459 cleaning agent Substances 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000001246 colloidal dispersion Methods 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000005757 colony formation Effects 0.000 description 1
• 201000010918 connective tissue cancer Diseases 0.000 description 1
• 230000009091 contractile dysfunction Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 230000005574 cross-species transmission Effects 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 208000024389 cytopenia Diseases 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 239000005549 deoxyribonucleoside Substances 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 229940115080 doxil Drugs 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 229940099302 efudex Drugs 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 229940087477 ellence Drugs 0.000 description 1
• 229940120655 eloxatin Drugs 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 210000000267 erythroid cell Anatomy 0.000 description 1
• 230000010437 erythropoiesis Effects 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 230000012173 estrus Effects 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
• 229960000752 etoposide phosphate Drugs 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 239000003337 fertilizer Substances 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 229940064300 fluoroplex Drugs 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 238000011773 genetically engineered mouse model Methods 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 238000009650 gentamicin protection assay Methods 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 230000007773 growth pattern Effects 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 229940003183 hexalen Drugs 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 229940088013 hycamtin Drugs 0.000 description 1
• 230000000640 hydroxylating effect Effects 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 229940090411 ifex Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 201000004933 in situ carcinoma Diseases 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000003317 industrial substance Substances 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
• 229940028435 intralipid Drugs 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 208000024312 invasive carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 201000004962 larynx cancer Diseases 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 210000000088 lip Anatomy 0.000 description 1
• 239000002960 lipid emulsion Substances 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 229940080194 liposyn iii Drugs 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 230000004777 loss-of-function mutation Effects 0.000 description 1
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 201000003175 male breast cancer Diseases 0.000 description 1
• 208000010907 male breast carcinoma Diseases 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229940087732 matulane Drugs 0.000 description 1
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 238000007855 methylation-specific PCR Methods 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
• 229960000907 methylthioninium chloride Drugs 0.000 description 1
• 108091058688 miR-141 stem-loop Proteins 0.000 description 1
• 108091089775 miR-200b stem-loop Proteins 0.000 description 1
• 108091059135 miR-429 stem-loop Proteins 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 238000007431 microscopic evaluation Methods 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• YGZIWEZFFBPCLN-UHFFFAOYSA-N n,3-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OOC1CCOP(=O)(NCCCl)N1CCCl YGZIWEZFFBPCLN-UHFFFAOYSA-N 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 231100001221 nontumorigenic Toxicity 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 229940064696 nutrilipid Drugs 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 201000005443 oral cavity cancer Diseases 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 238000010827 pathological analysis Methods 0.000 description 1
• VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 1
• 230000003836 peripheral circulation Effects 0.000 description 1
• 201000002628 peritoneum cancer Diseases 0.000 description 1
• 239000000575 pesticide Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229940063179 platinol Drugs 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229940071643 prefilled syringe Drugs 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000001480 pro-metastatic effect Effects 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 230000007425 progressive decline Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000002629 repopulating effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000003938 response to stress Effects 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 239000002342 ribonucleoside Substances 0.000 description 1
• 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• RCINICONZNJXQF-VAZQATRQSA-N s1150_selleck Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-VAZQATRQSA-N 0.000 description 1
• 201000003804 salivary gland carcinoma Diseases 0.000 description 1
• 230000002000 scavenging effect Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229940061353 temodar Drugs 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 101150118377 tet gene Proteins 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 239000005495 thyroid hormone Substances 0.000 description 1
• 229940036555 thyroid hormone Drugs 0.000 description 1
• 210000002105 tongue Anatomy 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 108091006107 transcriptional repressors Proteins 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 230000002100 tumorsuppressive effect Effects 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1